Trial Profile
Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis Allergic to Grass Pollen
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
- Focus Therapeutic Use
- 06 Dec 2011 Results published in Allergy.
- 19 Aug 2011 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.
- 19 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.